No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CABA Cabaletta Bio
- 12.820
- +1.590+14.16%
Trading May 15 15:54 ET
600.04MMarket Cap-7769P/E (TTM)
13.120High11.790Low845.97KVolume12.280Open11.230Pre Close10.69MTurnover2.23%Turnover RatioLossP/E (Static)46.80MShares26.35052wk High2.54P/B486.69MFloat Cap9.02052wk Low--Dividend TTM37.96MShs Float26.350Historical High--Div YieldTTM11.84%Amplitude0.590Historical Low12.638Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Cabaletta Bio's Promising Clinical Advancements and Stable Financial Outlook Merit a Buy Rating
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial results.Bolt Biotherapeutics posted a GAAP loss of 28 cent
William Blair Reaffirms Their Buy Rating on Cabaletta Bio (CABA)
NEXTracker Posts Upbeat Earnings, Joins Monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday.Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wednesday's session after the company reported better-than
Cabaletta Bio | 10-Q: Quarterly report
Cabaletta Bio Reveals Insights in Updated Corporate Presentation
Comments
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
23
$Cabaletta Bio(CABA.US$ isn't it great that we now punish good stocks with good news... they need to fix this crap, all these meidcal companies rely a lot on share prices...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
diamonds : 请问，ENDPQ重组后，持有的股票还能有效吗？